We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study (ELCIN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05596409
Recruitment Status : Not yet recruiting
First Posted : October 27, 2022
Last Update Posted : February 15, 2023
Sponsor:
Information provided by (Responsible Party):
Stemline Therapeutics, Inc.

Brief Summary:
The purpose of this study is to evaluate the efficacy and safety of elacestrant over the course of 6 months in patients with ER+/HER2- advanced/metastatic breast cancer who received no prior CDK4/6i in the metastatic setting.

Condition or disease Intervention/treatment Phase
Metastatic Breast Cancer Drug: Elacestrant Phase 2

Detailed Description:

This is a Phase 2 trial evaluating the efficacy of elacestrant in patients with estrogen receptor positive (ER+)/human epidermal growth factor receptor-2 negative (HER2-) advanced/metastatic breast cancer who received one or two prior hormonal therapies and no prior cyclin-dependent kinase targeting enzymes CDK4 and CDK6 inhibitor (CDK4/6i) in the metastatic setting.

The study duration for each patient is estimated to be:

  • Screening Phase: Up to 21 days prior to Cycle 1, Day 1 (C1/D1);
  • Treatment Phase: From C1/D1 until the date of radiologically documented progression, or treatment discontinuation due to other reasons.
  • Survival Follow-Up Phase: All patients will be followed for survival approximately every 3 months up to 24 months after enrollment of the last patient.

Patients will be followed for AEs for 28 days after the last treatment administration.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 80 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer: An Open-Label Multicenter Phase 2 Study (ELCIN)
Estimated Study Start Date : August 2023
Estimated Primary Completion Date : February 2024
Estimated Study Completion Date : August 2025

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: Elacestrant
Subjects will take a starting dose of 400 mg of elacestrant dihydrochloride in tablet form once daily for up to 6 months.
Drug: Elacestrant
Starting dose 400 mg elacestrant dihydrochloride administered orally once daily for an estimated 6 months of treatment.




Primary Outcome Measures :
  1. Progression-free survival rate [ Time Frame: 6 months ]
    Rate is defined as percentage of subjects achieving progression-free survival, defined as time from the date of the first dose to the date of the first radiological documentation of disease progression or death, whichever comes first.


Secondary Outcome Measures :
  1. Overall response rate [ Time Frame: 24 months ]
    Proportion of patients who achieve a best overall response of partial response or complete response

  2. Duration of response [ Time Frame: 36 months ]
    Time from the date of first documented complete response or partial response until the first radiological documentation of disease progression or death, whichever comes first

  3. Clinical benefit rate [ Time Frame: 36 months ]
    Proportion of patients who achieve a best overall response of confirmed complete response or partial response or durable stable disease (duration at least 24 weeks from date of first dose)

  4. Overall survival [ Time Frame: 36 months ]
    Time from the date of the first dose to the date of the first radiological documentation of disease progression or death, whichever comes first

  5. Progression-free survival [ Time Frame: 36 months ]
    Time from the date of the first dose to the date of the first radiological documentation of disease progression or death, whichever comes first



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patient has signed the informed consent before all study specific activities are conducted.
  2. Women or men aged ≥18 years (or the minimum age of consent as per local law), at the time of informed consent signature. Female patients may be either postmenopausal or premenopausal or perimenopausal.

    1. Premenopausal or perimenopausal women and men must be concurrently given a luteinizing hormone-releasing hormone (LHRH) agonist starting at least 4 weeks before the start of trial therapy and is planning to continue LHRH during the study.
    2. For perimenopausal women to be considered of non-childbearing potential, FSH levels must be >40 mIU/mL.
  3. Documentation of histopathologically or cytologically confirmed ER+, HER2-breast cancer, per local laboratory, as per the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines (Allison et al, 2020, Wolff et al, 2018). Note: In the context of this trial, ER status will be considered positive if ≥10% of tumor cells demonstrate positive nuclear staining by immunohistochemistry.
  4. Patient has received at least one (and up to two) prior hormonal therapy in the advanced/metastatic setting.
  5. At least one measurable lesion as per RECIST version 1.1 or a mainly lytic bone lesion. Note: Patients with stable brain or subdural metastases are allowed if the patient has completed local therapy and was on a stable or decreasing dose of corticosteroids at baseline for management of brain metastasis for at least 4 weeks before starting treatment in this study. The dose must be ≤2.0 mg/day of dexamethasone or equivalent. Any signs (e.g., radiologic) or symptoms of brain metastases must be stable for at least 4 weeks before starting study treatment.
  6. ECOG performance status of 0 or 1.
  7. Patient has adequate bone marrow and organ function, as defined by the following laboratory values:

    1. Absolute neutrophil count (ANC) ≥1.5 × 109/L
    2. Platelets ≥100 × 109/L
    3. Hemoglobin ≥9.0 g/dL
    4. Potassium, sodium, calcium (corrected for serum albumin) and magnesium CTCAE grade ≤1
    5. Cockcroft-Gault based creatinine clearance ≥50 mL/min. Note: Creatinine clearance (male) = ([140-age in years] × weight in kg)/ ([serum creatinine in mg/dL] × 72) Creatinine clearance (female) = (0.85 × [140-age in years] × weight in kg)/ ([serum creatinine in mg/dL] × 72)
    6. Serum albumin ≥3.0 g/dL (≥30 g/L)
    7. In absence of liver metastases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3.0 × upper limit of normal (ULN). If the patient has liver metastases, ALT and AST ≤5 × ULN
    8. Total serum bilirubin <1.5 × ULN except for patients with Gilbert's syndrome who may be included if the total serum bilirubin is ≤3.0 × ULN or direct bilirubin ≤ 1.5 × ULN.

Exclusion Criteria:

  1. Active or newly diagnosed central nervous system (CNS) metastases, including meningeal carcinomatosis.
  2. Patients with advanced, symptomatic visceral spread, that are at risk of life-threatening complications in the short term, including massive uncontrolled effusions (peritoneal, pleural, pericardial) and liver involvement of >50%.
  3. Prior chemotherapy, elacestrant, or CDK4/6i in the advanced/metastatic setting.
  4. Patient has a concurrent malignancy or history of invasive malignancy within 3 years of enrollment, with the exception of basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix that has completed curative therapy.
  5. Uncontrolled significant active infections.
  6. Patients with hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infection must have undetectable viral load during screening.
  7. Patients known to be HIV+ are allowed as long as they have undetectable viral load at baseline.
  8. Major surgery or radiotherapy within 28 days before starting trial therapy.
  9. Inability to take oral medication, refractory or chronic nausea, gastrointestinal condition (including significant gastric or bowel resection), history of malabsorption syndrome, or any other uncontrolled gastrointestinal condition that may impact the absorption of study drug.
  10. Known intolerance to elacestrant or any of its excipients.
  11. Females of childbearing potential who within 28 days before starting trial therapy, did not use a highly effective method of contraception.
  12. Females of childbearing potential who do not agree to use a highly effective method of contraception throughout the entire study period and for 28 days after trial therapy discontinuation. Note: Please refer to "Recommendations related to contraception and pregnancy testing in clinical trials" for additional details.
  13. Men who do not agree to abstain from donating sperm, or to use a highly effective method of contraception, during the course of the treatment period and for 120 days thereafter.
  14. Patient is currently receiving or received any of the following medications prior to first dose of trial therapy:

    1. Investigational anti-cancer therapy within 14 days (28 days in case of anticancer antibody-based treatments) or 5 half-lives, whichever is shorter.
    2. Fulvestrant treatment (last injection) <42 days before first dose of study drug.
    3. Any other endocrine therapy <14 days before first dose of study drug.
    4. Known strong or moderate inducers or inhibitors of cytochrome P450 (CYP) 3A4 within 14 days or 5 half-lives, whichever is shorter.
    5. Herbal preparations/medications within 7 days. These include, but are not limited to, St. John's wort, kava, ephedra (ma huang), gingko biloba, dehydroepiandrosterone (DHEA), yohimbe, saw palmetto, and ginseng.
  15. Evidence of ongoing alcohol or drug abuse as assessed by the investigator.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05596409


Contacts
Layout table for location contacts
Contact: William J Gradishar, MD 312-695-1301 cancer@northwestern.edu

Sponsors and Collaborators
Stemline Therapeutics, Inc.
Layout table for additonal information
Responsible Party: Stemline Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT05596409    
Other Study ID Numbers: STML-ELA-0322
First Posted: October 27, 2022    Key Record Dates
Last Update Posted: February 15, 2023
Last Verified: February 2023

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Stemline Therapeutics, Inc.:
metastatic breast cancer
breast cancer
elacestrant
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases